Clinical trial
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed…
NCT00364923 · Acrotech Biopharma Inc., Industry · Completed
Key facts
| NCT number | NCT00364923 |
|---|---|
| Title | Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
| Official title | A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
| Acronym | PROPEL |
| Lead sponsor | Acrotech Biopharma Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral T-cell Lymphoma |
| Intervention type | Drug |
| Interventions | Pralatrexate Injection |
| Enrollment | 115 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2009 |
| Completion | Feb 24, 2009 |
| First posted | Aug 16, 2006 |
| Last update posted | Dec 19, 2019 |
| Countries | Belgium, Canada, France, Italy, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: